Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 335

Posts Tagged ‘Seattle’

KKR Enters Seattle Real Estate Market

Posted by fidest press agency su giovedì, 26 dicembre 2019

KKR, a leading global investment firm, today announced the closing of two real estate transactions totaling over $1.2 billion located in the greater Seattle region, including the Summit located in downtown Bellevue and the F5 Tower in downtown Seattle.
The Summit is a 915,000-square-foot Class A office complex in the Bellevue central business district. The complex is 99% leased, and is comprised of two existing LEED Platinum office buildings and a third building currently under construction, expected to be completed in Q3 2020. The properties are well located in the heart of the central business district, one block from the Bellevue Transit Center and the Bellevue Downtown Light Rail Station opening in 2023.F5 Tower is a recently completed 43-story tower in the Seattle central business district, which includes the 100% leased 516,000-square-foot office condominium acquired by KKR alongside a separate 189-room luxury hotel. The property is architecturally significant to the Seattle skyline and home to F5 Networks as their global headquarters.The buildings will be operated by Urban Renaissance Group, a Seattle based real estate investor, developer, and manager of real estate, who assisted with the acquisitions.Since launching a dedicated real estate platform in 2011, KKR has invested or committed approximately $9 billion in capital across over 200 real estate transactions in the U.S., Europe and Asia as of September 30, 2019. KKR’s global real estate team consists of over 85 dedicated investment professionals, spanning both the equity and credit businesses.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Seattle Genetics Announces Pricing of Public Offering of Common Stock

Posted by fidest press agency su venerdì, 26 luglio 2019

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the pricing of an underwritten public offering of 7,142,858 shares of its common stock at a price to the public of $70.00 per share. All of the shares are being sold by Seattle Genetics. The gross proceeds to Seattle Genetics from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $500 million. The offering is expected to close on or about July 26, 2019, subject to customary closing conditions. In addition, Seattle Genetics has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,071,428 shares of its common stock solely to cover overallotments at the public offering price, less the underwriting discounts and commissions.Seattle Genetics anticipates using the net proceeds from the offering to fund ongoing commercialization of ADCETRIS in the United States and Canada, to fund its activities in preparation for the potential commercial launch of enfortumab vedotin, if approved by the FDA, to fund its research and development efforts designed to further expand the ADCETRIS label and to advance its pipeline of product candidates, as well as for general corporate purposes, including working capital. Seattle Genetics may also use a portion of the net proceeds to in-license, acquire or invest in complementary products, technologies, businesses or other assets or pursue other strategic opportunities although at this time Seattle Genetics has no material agreements or commitments with respect to any new in-license or acquisition opportunity.J.P. Morgan Securities LLC, SVB Leerink LLC and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering. Barclays Capital Inc., RBC Capital Markets, LLC and Guggenheim Securities, LLC are acting as co-managers for the offering.A shelf registration statement relating to the shares was previously filed with and became effective by rule of the Securities and Exchange Commission. The offering is being made solely by means of a prospectus. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the Securities and Exchange Commission and will be available on the Securities and Exchange Commission’s website located at

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Yapta Named One of the Best Places to Work by Built In Seattle

Posted by fidest press agency su martedì, 19 febbraio 2019

Yapta, the leading provider of airfare and hotel price tracking services, today announced it has been named one of this year’s 100 Best Places to Work in Seattle by Built In Seattle, an online community for Seattle startups and tech companies. The list recognizes Seattle businesses that go out of their way to provide employees with the support – both financial and non-financial – they need to thrive. Yapta was distinguished in two categories, including the “Small Companies” category and the “Overall” category. Among small companies, those with less than 100 employees, Yapta ranked 15th – and overall, it placed 75th. Built In’s Best Places to Work list rates companies algorithmically based on compensation and employer benefits information identified in its database. Compensation and benefits are weighted equally.More than 8,000 enterprise companies throughout the world – including 148 of Fortune 500 companies – utilize Yapta to track their airfare and hotel prices and capture significant savings. As the only company that provides total trip price assurance, Yapta’s IQ Technology has delivered more than $215 million in airfare and hotel savings to its corporate users. Corporate clients average a combined savings of $369 per trip by tracking both airfare and hotel prices in tandem.
In addition, Yapta has distribution agreements with 14 of the top 20 travel management companies (TMC) in the world, expanding its ability to continue its exceptional growth and scale. Yapta’s services are now live in 40 countries and uniquely able to meet the needs of global enterprises and mid-sized businesses, as well as small business customers through

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Seattle Genetics to Present at the J.P. Morgan Healthcare Conference

Posted by fidest press agency su venerdì, 21 dicembre 2018

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 2:30 p.m. Pacific Time. Both the presentation and question and answer session that follows at 3:00 p.m. will be webcast live and available for replay from Seattle Genetics’ website at in the Investors section.
Seattle Genetics, Inc. is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in people’s lives. ADCETRIS® (brentuximab vedotin) utilizes the company’s industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas. Beyond ADCETRIS, the company has established a pipeline of novel targeted therapies at various stages of clinical testing, including three in ongoing pivotal trials for solid tumors. Enfortumab vedotin for metastatic urothelial cancer and tisotumab vedotin for metastatic cervical cancer utilize our proprietary ADC technology. Tucatinib, a small molecule tyrosine kinase inhibitor, is in a pivotal trial for HER2-positive metastatic breast cancer. In addition, we are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors. The company is headquartered in Bothell, Washington, and has a European office in Switzerland. For more information on our robust pipeline, visit and follow @SeattleGenetics on Twitter.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Nissoli: Una settimana tra i giovani italiani che vivono in Usa

Posted by fidest press agency su lunedì, 13 febbraio 2017

nissoliLa scorsa settimana, l’on. Nissoli ha incontrato molti giovani di varie Comunità italiane presenti in Usa. In particolare, l’on. Nissoli si è recata a Seattle e all’Università dell’Alabama. A Seattle, assieme al Console onorario Franco Tesorieri, ha incontrato i giovani ricercatori italiani che lavorano nel polo tecnologico della zona. “Una Comunità – ha detto l’on. Nissoli – vivace e che potrebbe dare tanto all’Italia, a cominciare da quei giovani che hanno lasciato la terra d’origine per fare un’ esperienza all’avanguardia nella terra dell’information technology, qui in Usa”. Invece, all’Università dell’Alabama, l’on. Nissoli, parlando delle politiche per gli italiani all’estero, ha detto: “Voglio realizzare il sogno di una Italia che consideri gli italiani all’estero cittadini a tutti gli effetti e sto lavorando per questo, con fatica ma senza perdermi d’animo, a cominciare dalla battaglia per il riacquisto della cittadinanza per chi, andato all’estero, l’ha perduta”. Invece, per quanto concerne il Progetto “Cervelli in Viaggio”, promosso da Massimo Veccia,che ha concluso, questa settimana, la sua fase americana a New York, l’on. Nissoli ha ricordato che tale Progetto formativo “aiuta i giovani ad entrare preparati sia nel mondo dell’impresa che si affaccia ed opera nei contesti internazionali sia ad apportare in contesti produttivi italiani un bagaglio di best practice che può essere utile per il miglioramento dell’efficacia e dell’efficienza delle strutture aziendali”. “E’ stata una settimana intensa di incontri – ha riassunto l’on. Nissoli – con giovani pieni di speranza e di amore per l’Italia; momenti belli di umanità e politica che mi danno la forza di lavorare con ancora più convinzione per il mio Paese, il Paese che noi tutti italiani all’estero portiamo sempre nel cuore, in qualsiasi contesto.” (foto: nissoli)

Posted in Estero/world news, Università/University | Contrassegnato da tag: , , | Leave a Comment »

Staffordshire University Uses Verdiem Power Management Software

Posted by fidest press agency su mercoledì, 18 aprile 2012

London, (PRNewswire) Full return-on-investment expected within a single year Verdiem, a leader in IT energy management and efficiency software, has successfully deployed its Surveyor solution at Staffordshire University. In an effort to control rising electricity costs, and as part of its ongoing Green Initiative drive, Staffordshire University selected Verdiem Surveyor to help reduce power wastage across its estate of over 4,000 PCs deployed across multiple sites for staff and student use. Steve Bignell, Technical Director for Verdiem, explains: “When you’re a large organisation such as Staffordshire University with thousands of PCs spread out across multiple locations and campuses, thousands of pounds worth of wasted power consumption are generated when PCs are left on but not used. With power costs continuing to rise, the opportunity to make savings through more efficient energy usage is an attractive bottom-line gain.”Verdiem helped define the PC power management market and has now extended its leadership into IT energy management and efficiency software. Verdiem Surveyor enables customers to centrally control and reduce the energy used by PCs, Macs, and network devices running Cisco EnergyWise without impacting end users. Nearly 700 corporations, government agencies and universities have deployed Surveyor on 2 million devices. Based in Seattle, Wash., Verdiem is backed by Kleiner Perkins Caufield & Byers. More information is available at or (206) 838-2800.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems

Posted by fidest press agency su venerdì, 6 gennaio 2012

Cell Culture in a tiny Petri dish.

Image via Wikipedia

Copenhagen, Denmark and SeattleCMC Biologics, a leading biopharmaceutical contract manufacturing organization, announced the issuance of European Patent No. US 2,171,034 B1 covering a method for improving productivity in microbial fermentations and mammalian cell culture bioreactors. The invention is designed to optimize production of a biotherapeutic in a continuous perfusion fermentation process, wherein the bioreactor (fermenter) has an ultrafiltration system that allows impurities to be removed while retaining cells in the bioreactor. Perfusion bioreactors involve continuous cell culture, feeding, and withdrawal (harvesting) of product and accumulates no waste products, thereby creating a stable cell growth environment. Optimal environmental conditions can be precisely controlled with this new technology resulting in increased productivity due to increased cell density in the reactor and in particular, a significant higher concentration of the product in the harvested medium. The expressed biologics are rapidly removed and made available for purification at high concentration – a significant advantage for the downstream processing.
CMC Biologics ( is a global contract biopharmaceutical manufacturing and development organization with facilities in Copenhagen, Denmark and Seattle, Washington, USA. CMC Biologics specializes in custom services for scale up and cGMP manufacture of protein-based therapeutics for preclinical, clinical trials, and in-market production. The Company’s fully integrated services includes cell line development using its proprietary CHEF1® system, process and formulation development, and comprehensive analytical testing. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers stirred tank and perfusion production processes.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »